Jun 2026 (Q2 FY26) — Aug 13, 2026
Nomad Foods Q2 FY26 — Price/Mix Inflection and Margin Expansion Amid Category Strength
Read the full callNomad Foods (NOMD) earnings
- Jun 2026 (Q2 FY26)
- Dec 2025
Nomad Foods earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Price
$11.7 −0.51% · −$0.06
Performance −4.3% 1Y
1Y: $12.22 on 17 Oct 2025 → $11.7. High $13.04 (20 Feb 2026), low $9.09 (13 May 2026).
- Previous close
- $11.76
- 52-week range
- $9.09 – $13.04
- One year
- −2.74%
Overview
- Symbol
- NOMD
- Sector
- Consumer Staples
- Industry
- Food and Kindred Products
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Nomad Foods earnings calls (NOMD)
Financials
What the filings say
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | 3,758 | 3,761 | 4,239 | 4,385 | 3,968 | 4,226 | 3,916 | 4,510 |
| Fixed assets | 399 | 393 | 458 | 554 | 527 | 554 | 539 | 620 |
| Total assets | 6,115 | 6,633 | 6,848 | 6,989 | 6,747 | 7,090 | 6,682 | 7,444 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 368 | 354 | 561 | 347 | 324 | 476 | 452 | 389 |
| Cash from investing | -588 | -83 | -210 | -748 | -84 | -85 | -67 | -88 |
| Cash from financing | 347 | 282 | -877 | 243 | -115 | -355 | -381 | -390 |
| Capital expenditure | -48 | -53 | -72 | -90 | -84 | -91 | -83 | -92 |
| Free cash flow | 320 | 301 | 489 | 257 | 240 | 385 | 369 | 296 |
Insider filings
19 filings between May 6, 2026 and Aug 24, 2026.
Open market
decisions to buy or sellPurchases
$10.11M
7 purchases by 4 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 5
- Award — granted as compensation
- 5
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Gottesman Noam | $6.63M | — | May 12, 2026 |
| BRISBY DOMINIC | $2.09M | — | Aug 24, 2026 |
| ASHKEN IAN G H | $912.7K | — | May 13, 2026 |
| BALDEW RUBEN | $478.3K | — | Aug 19, 2026 |
Latest filings (19)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 24, 2026 | BRISBY DOMINIC Chief Executive Officer | Purchase | 50,000 | $619.0K |
| Aug 19, 2026 | BALDEW RUBEN Chief Financial Officer | Purchase | 28,290 | $335.2K |
| Jul 2, 2026 | PARRY VICTORIA Director | Tax withheld | 4,021 | $40.3K |
| Jul 2, 2026 | PILOWSKY AMIT Director | Tax withheld | 3,729 | $37.4K |
| Jul 2, 2026 | STACK MELANIE DAWN Director | Tax withheld | 4,021 | $40.3K |
| Jul 2, 2026 | Dorman Carey J. Director | Tax withheld | 1,676 | $16.8K |
| Jul 2, 2026 | LILLIE JAMES E Director | Tax withheld | 3,580 | $35.9K |
| Jun 22, 2026 | PARRY VICTORIA Director | Award | 13,972 | $0 |
| Jun 22, 2026 | LILLIE JAMES E Director | Award | 13,972 | $0 |
| Jun 22, 2026 | Dorman Carey J. Director | Award | 22,654 | $0 |
| Jun 22, 2026 | PILOWSKY AMIT Director | Award | 21,656 | $0 |
| Jun 22, 2026 | STACK MELANIE DAWN Director | Award | 21,856 | $0 |
| May 15, 2026 | BRISBY DOMINIC Chief Executive Officer | Purchase | 150,000 | $1.47M |
| May 14, 2026 | BALDEW RUBEN Chief Financial Officer | Purchase | 14,731 | $143.1K |
| May 13, 2026 | ASHKEN IAN G H Director | Purchase | 100,000 | $912.7K |
| May 12, 2026 | Gottesman Noam Director | Purchase | 200,000 | $1.85M |
| May 11, 2026 | Gottesman Noam Director | Purchase | 500,000 | $4.79M |
| May 6, 2026 | FRANKLIN MARTIN E Director | Other | 220,000 | $0 |
| May 6, 2026 | FRANKLIN MARTIN E Director | Other | 220,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Nomad Foods Ltd
Free account. Everything above stays public.
Write why you follow Nomad Foods Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading